Close

Reauthorization of the Prescription Drug User Fee Act

Mar 6 2002
The Prescription Drug User Fee Act has been and remains an extraordinarily successful piece of legislation.

Supporting the Passage of Trade Promotion Authority Without Accompanying Amendments

Mar 6 2002

Letter, United States Senate

BIO Supports the Biological and Chemical Weapons Research Act

Mar 3 2002
BIO supports S. 1764, the Robert Stevens, Thomas Morris Jr., Joseph Curseen, Kathy Nguyen, Ottilie Lundgren, and Lisa Raines Biological and Chemical Weapons Research Act as introduced by Senator Joseph Lieberman. (Mar. 3, 2002).

Law and Policy in the Knowledge E-Based Economy

Feb 26 2002
The biotechnology industry is the most research and development intensive and capital-focused industry in the world. As such, it is very dependent on a robust intellectual property system as well as a strong set of competition laws.

BIO Director Testifies In Senate Hearing

Feb 5 2002
Meeting the Bioterrorism Threat with Cooperation Between the Federal Government and Biotechnology Industry (Feb. 5).

History of Pediatric Studies, Rule, Legislation and Litigation

Jan 8 2002

...

FDA Stakeholders Meeting

Dec 7 2001
Since its inception, PDUFA has worked. The law has led to reduced review and approval times. This has meant that patients have had access to new therapies and diagnostics faster. Put simply, this law has both changed and saved lives.

Letter to Carl B. Feldbaum, BIO President from Samual W. Bodman, Deputy Secretary of Commerce

Nov 15 2001
Regarding funding for the U.S. Patent and Trademark Office

BIO letter to J. Dennis Hastert

Nov 5 2001

Economic Fundamentals Sound: Deal-Making within the Biotechnology Industry

Oct 29 2001
At a time when national security is understandably monopolizing Congress's legislative calendar, as well as the energies of the federal agencies that regulate biotechnology, I am pleased to report that the biotechnology industry's fundamentals are sound.